Drugs / RNA CART19 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02624258 | Nov 2015 → Jun 2019 | Hodgkins lymphoma | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA CART19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02624258 ↗ |
| Known as | CART19 | “using anti-CD19-directed CAR-modified T cells (CART19) may indirectly affect HRS cells” PMID 29925499 ↗ Jun 2018 |
| Action | Deplete | “We hypothesized that eradicating CD19+ B cells within the TME and the putative circulating CD19+ HRS clonotypic cells using anti-CD19-directed CAR-modified T cells (CART19) may...” PMID 29925499 ↗ Jun 2018 |
| Modality | Cell therapy | “CAR-modified T cells are being investigated in many settings, including classical Hodgkin lymphoma (cHL).” PMID 29925499 ↗ Jun 2018 |
| Route | Intravenous | “IV administration of RNA anti-CD19 CAR T cells” NCT02624258 ↗ |
| Target | CD19 | “using anti-CD19-directed CAR-modified T cells (CART19) may indirectly affect HRS cells” PMID 29925499 ↗ Jun 2018 |